|
Synonyms: ALN-AS1 | Givlaari®
givosiran is an approved drug (FDA (2019))
Compound class:
Nucleic acid
Comment: Givosiran (ALN-AS1) is a double-stranded N-acetylgalactosamine (GalNAc)-conjugated small interfering ribonucleic acid (siRNA) drug. It inhibits hepatic synthesis of 5'-aminolevulinate synthase 1 as a mechanism to reduce accumulation of toxic heme intermediates in patients with acute hepatic porphyria (which arises from deficient aminolevulinic acid dehydratase and porphobilinogen deaminase activities). GalNAc-conjugation is a strategy used to promote delivery of the drug to the liver [1]- this is annotated as 'R1' in the sequence provided here. We have been unable to locate a full chemical SMILES for the drug, or its HELM notation.
|
| References |
|
1. Holm A, Løvendorf MB, Kauppinen S. (2021)
Development of siRNA Therapeutics for the Treatment of Liver Diseases. Methods Mol Biol, 2282: 57-75. [PMID:33928570] |
|
2. Honor A, Rudnick SR, Bonkovsky HL. (2021)
Givosiran to treat acute porphyria. Drugs Today (Barc), 57 (1): 47-59. [PMID:33594389] |
|
3. Scott LJ. (2020)
Givosiran: First Approval. Drugs, 80 (3): 335-339. [PMID:32034693] |
